Department of Combinatorial Chemistry, Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine,150 Zabolotnogo Street, 03143 Kyiv, Ukraine.
Eur J Med Chem. 2011 Mar;46(3):870-6. doi: 10.1016/j.ejmech.2010.12.025. Epub 2011 Jan 9.
A novel series of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids has been synthesized and tested in vitro towards human protein kinase CK2. It was revealed that the most active compounds inhibiting CK2 are 3-{[5-(4-methylphenyl)thieno[2,3-d]pyrimidin-4-yl]thio}propanoic acid and 3-{[5-(4-ethoxyphenyl)thieno[2,3-d]pyrimidin-4-yl]thio}propanoic acid (IC(50) values are 0.1 μM and 0.125 μM, respectively). Structure-activity relationships of 28 tested thienopyrimidine derivatives have been studied and binding mode of this chemical class has been predicted. Evaluation of the inhibitors on seven protein kinases revealed considerable selectivity towards CK2.
已经合成了一系列新型取代的（噻吩并[2,3-d]嘧啶-4-基硫代）羧酸，并对其进行了体外人蛋白激酶 CK2 的测试。结果表明，抑制 CK2 活性最强的化合物是 3-[[5-(4-甲基苯基)噻吩并[2,3-d]嘧啶-4-基]硫代]丙酸和 3-[[5-(4-乙氧基苯基)噻吩并[2,3-d]嘧啶-4-基]硫代]丙酸（IC50 值分别为 0.1 μM 和 0.125 μM）。对 28 种测试的噻吩并嘧啶衍生物的构效关系进行了研究，并预测了该类化合物的结合模式。对七种蛋白激酶的抑制剂进行评估，结果表明其对 CK2 具有相当的选择性。
